CGM-Pump System Integration Patent Snapshot 2026
The patent corpus for CGM-pump system integration is extremely small, with Animas Corporation holding a dominant position and just two applicants represented in the current evidence set. Filing activity has been largely dormant across the observed window, suggesting that substantive innovation in this narrowly defined query space is concentrated in a single legacy portfolio.
Animas Corporation leads a highly concentrated, two-player corpus
Animas Corporation ranks first with 6 patent records, followed at a distance by PRIMEWISE TEKNOLOJI AS with 1 patent record. The top five filers account for 100% of the ranked applicants visible in this query’ combined total, signalling near-total concentration in a single incumbent.
The tier gap between the leader and the only other identified applicant is pronounced: Animas holds six times the patent records of its nearest rival. This level of concentration is atypical even for niche medical-device sub-fields and reflects the narrowly scoped query rather than the broader closed-loop insulin-delivery sector.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Animas Corporation | 6 | |
| 2 | PRIMEWISE TEKNOLOJI AS | 1 |
Animas Corporation’s visible position implies that any entrant seeking freedom-to-operate or licensing leverage in this specific CGM-pump integration framing must engage with its portfolio directly. The emergence of PRIMEWISE TEKNOLOJI AS as a new entrant signals that at least some new activity is occurring, though at minimal scale in the current evidence.
The most recent filing periods should be treated with caution given typical 18-to-24-month publication lag; the absence of records in 2022–2026 may not fully reflect actual recent activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Sparse filings clustered in diagnosis and fluid-delivery branches
The annual trend and technology composition charts together reveal both the temporal distribution of filings and the IPC branches that define the current patent space for CGM-pump integration.
Annual filing trend
A single filing appears in 2017, followed by zero activity through 2023, with one filing recorded in 2024. The near-complete absence of activity across the interval suggests the evidence set is a narrow slice of a broader innovation landscape; publication lag means 2024 and later years are likely under-represented. No reliable growth trend can be read from two data points.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Three IPC branches — A61B (Diagnosis & surgery), A61M (Devices for body fluids), and G16H (Healthcare informatics) — each carry 6 patent records, reflecting the multi-disciplinary nature of closed-loop pump-CGM architectures. G06F (Electric digital data processing) is represented by 2 patent records, indicating that software and data-processing claims are present but subordinate to clinical-device branches in this corpus.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Method and system for closed-loop control of an ar…
Methods and systems for controlling an insulin pump in response to glucose measurements are responsive to a base insulin delivery profile and a temporary insulin delivery profile. These can be used, e.g., to control blood glucose level of a subject using a continuous glucose monitor and an insulin infusion pump. During a selected time range, an insulin… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Method and system for closed-loop control of an ar… | 161 |
| 2 | Method and system for closed-loop control of an ar… | 71 |
| 3 | Method and system for closed-loop control of an ar… | 29 |
| 4 | Method and system for closed-loop control of an ar… | 12 |
| 5 | Method and system for closed-loop control of an ar… | 12 |
| 6 | System for closed-loop control of an artificial pa… | 1 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Animas Corporation
Animas Corporation holds 6 patent records, all concentrated across A61M 5 (devices for body fluids), G16H 20, and G16H 40 (healthcare informatics) — the core claim space for closed-loop CGM-pump control systems. No momentum data is available for Animas in the recent period, consistent with its legacy portfolio status. Freedom-to-operate analysis should focus on the A61M and G16H claim sets.
patent records: 6PRIMEWISE TEKNOLOJI AS
PRIMEWISE TEKNOLOJI AS enters as a new entrant with 1 patent record, positioned in A61B 5 (diagnosis and surgery) — a branch adjacent to but distinct from Animas’s fluid-delivery focus. Its trajectory is flagged as a new entrant, meaning prior-period baseline is zero; the single recent record should be interpreted cautiously rather than as evidence of a sustained filing program.
patent records: 1Frequently asked questions
Animas Corporation leads the evidence set with 6 patent records, representing the entirety of the top-ranked portfolio in this narrowly defined query space.
Europe (EPO) and the United States each account for 3 patent records, with WIPO (PCT) holding 1 record. The parallel EPO-US strategy reflects the dual regulatory pathway required for medical-device commercialisation in those markets.
A61B (Diagnosis and surgery), A61M (Devices for body fluids), and G16H (Healthcare informatics) each carry 6 patent records. G06F (Electric digital data processing) is present but less prominent with 2 records.
The current evidence set is too small — 2 patent families — to establish a reliable filing trend. A single record appears in 2017 and one in 2024, with no activity in between. Publication lag also means recent years may be under-represented. A broader landscape search is needed before drawing growth conclusions.
No co-applicant or collaborative filing relationships are recorded in the current evidence set. Whether this reflects genuine absence of collaboration in the wider sector or the narrowness of the query is unclear; broader searches are recommended.
The highest-cited item in the evidence set is titled ‘Method and system for closed-loop control of an artificial pancreas,’ with 161 citations, consistent with Animas Corporation’s focus on closed-loop pump-CGM architectures combining A61M and G16H claim sets.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.